Peptech: Domantis signs licence agreement with Tanox
09:50, Wednesday, 23 March 2005
Sydney - Wednesday - March 23: (RWE Australian Business News) - Peptech Ltd (PTD) today announced the signing of a collaboration and licence agreement between Domantis Ltd (UK) and Tanox Inc (USA) for the use of domain antibodies in the treatment of autoimmune diseases. As part of the deal Domantis, the domain antibody therapeutics company in which Peptech holds a 36.1 per cent interest, will receive an undisclosed upfront fee, research funding and annual fees, as well as milestones and royalties on the therapeutic products developed and commercialised by Tanox. Tanox, a leading US biotechnology company, already has a successful history in developing antibody therapeutics, which includes the asthma drug Xolair.
Once buy-back starts, PTD will move to 2.00
PTD Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held